Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 3270-3276

  Mammen, Jennifer S ^a   Ghazarian, Sharon R ^a   Pulkstenis, Erik ^b   Subramanian, G Mani ^c   Rosen, Antony ^a   Ladenson, Paul W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; PEGINTERFERON ALPHA2A; THYROID ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; THYROID DISEASE; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HEPATITIS C; HUMANS; HYPOTHYROIDISM; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; SEX CHARACTERISTICS; THYROID DISEASES; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN; THYROXINE; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84866157120     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1026     Document Type: Article

References (24)

1. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH 1992 Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102:2155-2160
2. Costelloe SJ, Wassef N, Schulz J, Vaghijiani T, Morris C, Whiting S, Thomas M, Dusheiko G, Jacobs M, Vanderpump MP 2010 Thyroid dysfunction in a UK hepatitis C population treated with interferonalpha and ribavirin combination therapy. Clin Endocrinol (Oxf) 73:249-256
3. Tran HA, Reeves GE, Ianna EA, Leembruggen N 2010 Thyroid function outcomes after pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Endocr Pract 16:934-939
4. Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C 2009 Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 15:328-333
5. Jamil KM, Leedman PJ, Kontorinis N, Tarquinio L, Nazareth S, McInerney M, Connelly C, Flexman J, Burke V, Metcalf C, Cheng W2009 Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol 24:1017-1023
6. Tran HA, Malcolm Reeves GE, Gibson R, Attia JR 2009 Development of thyroid diseases in the treatment of chronic hepatitis C with α-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol 24:1163-1168
7. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara AM, Jiménez-Rivera J 2008 Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol 7:72-77 (Pubitemid 351468541)
8. Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, Lachkar H, Benaissa A 2006 Thyroid disorders during interferon α therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 67:343-347
9. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, Wang PW 2006 Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. J Gastroenterol Hepatol 21(1 Pt 2):319-326
10. Moncoucy X, Leymarie F, Delemer B, Lévy S, Bernard-Chabert B, Bouché O, Jolly D, Diebold MD, Cadiot G, Thiéfin G 2005 Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 29:339-345 (Pubitemid 40646477)
11. Bini EJ, Mehandru S 2004 Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 164:2371-2376 (Pubitemid 39532250)
12. Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H 2002 Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: No association with either interferon dosage or efficacy of therapy. J Intern Med 251:400-406 (Pubitemid 34534115)
13. Ioannou Y, Isenberg DA 2000 Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431-1442 (Pubitemid 30452458)
14. Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M 1999 HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 30:794-800 (Pubitemid 29248978)
15. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S 1997 Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 26:206-210 (Pubitemid 27280326)
16. Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, Vitti P, Serio M, Ferrannini E 2010 Interferon-α, -β, and -γ induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-γ agonists. Cytokine 50:260-267
17. Akeno N, Smith EP, Stefan M, Huber AK, Zhang W, Keddache M, Tomer Y 2011 IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 186:4693-4706
18. Tomer Y, Menconi F 2009 Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 23:703-712
19. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG, ACHIEVE-1 Study Team 2010 Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 139:1257-1266
20. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489-499 (Pubitemid 34158210)
21. Nikolai TF, Turney SL, Roberts RC 1987 Postpartum lymphocytic thyroiditis. Prevalence, clinical course, and long-term follow-up. Arch Intern Med 147:221-224 (Pubitemid 17040235)
22. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE 2007 National Health and Nutrition Examination Survey III thyroidstimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab 92:4236-4240 (Pubitemid 350074737)
23. Surks MI, Hollowell JG 2007 Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 92:4575-4582 (Pubitemid 350223429)
24. Calvaruso V, Craxi A 2012 2011 european association of the study of the liver hepatitis C virus clinical practice guidelines. Liver Int 32(Suppl 1):2-8